Mission Statement, Vision, & Core Values (2026) of PerkinElmer, Inc.

Step into the world of PerkinElmer, Inc., a global life-sciences and diagnostics powerhouse that for over 85 years has enabled scientists, clinicians and public-health teams across 190 countries to diagnose disease, develop personalized drugs and safeguard food and the environment, backed by a workforce of more than 16,000 professionals and annual revenues near $5 billion, now doubling down on a strategic realignment toward human and environmental health and bold sustainability targets such as achieving net carbon neutrality by 2040 that drive its mission to innovate for a healthier world, a vision of enduring greatness, and core values of integrity, collaboration, customer focus, accountability and inclusion that power its R&D, diagnostics, instruments, assays and services.

PerkinElmer, Inc. (PKI) - Intro

• Founded: 1937
• Global footprint: ~190 countries
• Employees: >16,000
• 2022 Revenue: ~ $5.0 billion
• Strategic realignment (2023): Focus on human and environmental health

• Enable healthier lives and safer environments through innovative diagnostics, services, reagents, instruments, automation, and informatics.
• Deliver actionable insights that accelerate scientific discovery and clinical decision-making.
• Provide scalable solutions that meet regulatory, quality, and safety needs across sectors.

• Create a healthier, cleaner, and safer world by integrating human and environmental health priorities into every product and service.
• Be the partner of choice for laboratories, hospitals, governments, and industries seeking trusted, end-to-end solutions.
• Drive precision health and environmental stewardship through innovation, data, and collaboration.

• Scientific Excellence - rigorous, evidence-driven innovation in assays, instruments, and informatics.
• Customer-Centricity - focused on delivering measurable outcomes and operational value to diverse customers.
• Integrity & Compliance - strong governance, ethical conduct, and adherence to regulatory standards.
• Sustainability & Responsibility - commitment to ESG initiatives that reduce environmental impact and support communities.
• Collaboration & Inclusion - leveraging cross-functional teams and diverse perspectives to solve complex challenges.

• End-to-end solutions: reagents, assays, instruments, automation, informatics, and strategic services that span discovery to diagnostics.
• Growth levers: expanding diagnostics and precision medicine offerings, scaling environmental health solutions, and advancing digital/informatics platforms.
• Operational focus: integrate R&D with commercial execution to drive recurring revenue and service-based engagements.

• Active ESG engagement: sustainability programs, responsible sourcing, and community health initiatives aligned with the 2023 strategic realignment.
• Workforce investments: training, safety programs, and diversity initiatives across >16,000 employees.
• Transparency: reporting on environmental footprint, governance practices, and social impact as part of corporate disclosure efforts.

PerkinElmer, Inc. (PKI) - Overview

• Core mission focus: accelerate detection, diagnostics, and monitoring capabilities to improve patient outcomes and environmental safety.
• Strategic emphasis: combine instrumentation, reagents, software, and services to deliver end‑to‑end workflows for laboratories, hospitals, and industrial customers.
• Global ambition: align product development with public‑health needs (infectious disease testing, neonatal screening, oncology, toxicology, environmental monitoring).

• Continuous improvement: iterative product upgrades, software analytics, and workflow automation to increase throughput, sensitivity, and usability.
• R&D investment: sustained capital allocation to research programs, partnerships with academic centers, and product commercialization pipelines.
• Translation to impact: focus on diagnostic assays, consumables, and digital solutions that shorten time to diagnosis and improve laboratory efficiency.

• Scientific excellence - prioritizing robust, validated methodologies and regulatory compliance.
• Customer commitment - co‑creating solutions with clinical and environmental lab partners.
• Integrity and quality - product reliability and data integrity across diagnostics and screening workflows.
• Collaboration and inclusion - cross‑discipline teams accelerating innovation and market adoption.

• Capital allocation: meaningful budget toward R&D, targeted acquisitions to expand assay portfolios, and manufacturing scale for high‑volume consumables.
• Commercial reach: global distribution network serving clinical labs, research institutions, pharma, and environmental agencies.
• Technology platforms: integrated instrumentation + reagent ecosystems and data analytics to improve diagnostic sensitivity and lab throughput.

• Diagnostics throughput: solutions designed to increase specimen throughput across newborn screening, infectious disease, and oncology testing programs.
• Environmental monitoring: instrumentation and consumables used for trace‑level detection of contaminants across water, food, and air testing programs.
• Partnerships: collaborations with public‑health agencies and academic centers to validate assays and deploy screening programs in resource‑constrained settings.

PerkinElmer, Inc. (PKI) - Mission Statement

• Focus: Create a healthier, cleaner, and safer world through scientific advancements.
• Approach: Preserve core values while evolving commercial and R&D strategies to meet shifting market dynamics.
• Outcome: Sustainable growth and strengthened leadership in diagnostics, applied markets, and life sciences instruments and reagents.

• Invest in platform innovation (instruments, assays, software) to accelerate translational research and diagnostic throughput.
• Expand service and consumables recurring revenue to improve margin stability and predictability.
• Drive geographic diversification and partnerships to capture emerging-market growth and resilience against regional headwinds.

• Operational agility: rapid reallocation of manufacturing and supply chains during demand shifts.
• Product pipeline focus: prioritizing high-impact assays, automation, and cloud-enabled analytics.
• Ethical stewardship: environmental, health & safety initiatives aligned with long-term societal goals.

• Revenue growth and recurring revenue ratio
• R&D efficiency (new product contribution to revenue)
• Gross margin and adjusted EBITDA expansion
• Customer retention and installed-base utilization rates

PerkinElmer, Inc. (PKI) - Vision Statement

• Deliver diagnostic and analytical solutions that accelerate scientific discovery, improve clinical outcomes, and protect environmental health globally.
• Leverage technology and data to enable earlier detection, higher-quality care, and more sustainable operations for customers and communities.
• Create long-term shareholder value by marrying scientific excellence with operational discipline and market-focused innovation.

• Integrity - Ethical conduct is a cornerstone: compliance, transparent reporting, and strong governance underpin operations across PKI's global footprint.
• Customer Focus - Product development, service models, and digital engagement are oriented to improve customer experience and satisfaction metrics across diagnostics, life sciences, and environmental markets.
• Collaboration - Cross-functional teamwork and external partnerships (academic, industry, public-health) amplify innovation and speed-to-market.
• Accountability - Clear ownership of outcomes drives performance management, continuous improvement cycles, and measurable KPIs at business-unit and corporate levels.
• Diversity, Equity & Inclusion - Commitment to inclusive hiring, leadership development, and equitable policies to reflect and better serve a global customer base.
• Sustainability - Ambitious environmental targets guide operations and product design, including a pledge to reach net carbon neutrality by 2040.

• Net carbon neutrality target: 2040.
• Scope 1 & 2 emissions reduction: 30% by 2030 (baseline-aligned target for near-term action).
• Operational programs: energy efficiency retrofits, renewable procurement, and low-carbon product development roadmaps to reduce lifecycle impacts.

• Customer-centric innovation: prioritize products and services that reduce time-to-result, increase diagnostic accuracy, and lower total cost of ownership for customers.
• Sustainable operations: embed emissions reductions and circularity into manufacturing, packaging, and product life-cycle strategies.
• Global access and equity: expand diagnostic and testing reach in underserved markets through partnerships and scalable business models.
• Talent and culture: cultivate diverse leadership pipelines and metrics-driven accountability for inclusion and performance.

• KPIs link R&D throughput, customer NPS, product uptime, and sustainability progress to executive compensation and board oversight.
• Annual sustainability reporting and third-party assurance support transparency on emissions, energy use, and progress toward targets.
• Cross-functional steering committees ensure integrity, compliance, and alignment between commercial goals and ESG commitments.